EUVIMEDEUVIMED entdecken
Crossref

Lansoprazole Enhances Everolimus Efficacy Through DDIT3 ‐Mediated PI3K / AKT /mTOR Pathway Inhibition in Pancreatic Neuroendocrine Neoplasms Proliferation

Xinyun Qiang, Guozhi Zhou, Ruitong Xu, Fengjuan Chen, Jieyu Lu, Wei Sun, Ye Tian, Xiaojun Yang, Qiyun Tang, Mujie Ye iD

The FASEB Journal · 15.04.2026 · 40 (7)

DOI: 10.1096/fj.202600037r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 30.03.2026. Verfasst von Xinyun Qiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroendocrine Tumor, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Everolimus, TOR Serine-Threonine Kinases, Pancreatic Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Key Discipline Program of Wuxi Health Commission, Scientific Research Program of Wuxi Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic neuroendocrine neoplasms (PanNENs) represent a rare and heterogeneous group of tumors with diverse biological behaviors and clinical outcomes, posing significant therapeutic challenges. Recent studies have suggested that certain proton pump inhibitors, including Lansoprazole, may possess direct anti‐tumor properties beyond their classical role in acid suppression; however, their specific effects and molecular mechanisms in PanNENs remain largely unexplored. This study aims to investigate the anti‐proliferative effects and elucidate the underlying molecular mechanisms of Lansoprazole in PanNEN models. Our findings demonstrate that Lansoprazole significantly upregulates the expression of DNA Damage Inducible Transcript 3 (DDIT3), a key stress‐induced transcription factor. This upregulation leads to the subsequent inhibition of the oncogenic PI3K/AKT/mTOR signaling pathway, a central driver of cell growth and proliferation, resulting in marked suppression of PanNEN cell proliferation in vitro. Furthermore, we explored combination therapy strategies and found that Lansoprazole synergizes with everolimus, an established mTOR inhibitor used in PanNEN treatment. This combination enhances overall anti‐tumor efficacy, suggesting a promising synergistic therapeutic strategy for PanNENs. These results not only reveal a novel, drug‐repurposing approach for targeting PanNENs but also provide a mechanistic rationale for combining Lansoprazole with standard targeted therapies to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusTOR Serine-Threonine KinasesPancreatic NeoplasmsProto-Oncogene Proteins c-aktNeuroendocrine TumorsLansoprazolePhosphatidylinositol 3-KinasesHumansCell ProliferationSignal TransductionCell Line, TumorDrug SynergismAnimalsMTOR Inhibitors

Stichwörter der Autor:innen

DDIT3EverolimusLansoprazolePI3K‐AKT–mTOR signaling pathwayPancreatic neuroendocrine neoplasms

Substanzen

EverolimusTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktLansoprazoleMTOR protein, humanPhosphatidylinositol 3-KinasesMTOR Inhibitors

Autor:innen und Institutionen

  • Department of Neuroendocrine Tumor, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Neuroendocrine Tumor Diagnosis and Treatment Center of Jiangsu Province, Nanjing, China.
  • Institute of Neuroendocrine Tumor of Nanjing Medical University, Nanjing, China.
  • Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Gastroenterology, Xishan People's Hospital of Wuxi City, Wuxi, China.

ORCID-Profile: Mujie Ye

Förderung

  • National Natural Science Foundation of China
  • Medical Key Discipline Program of Wuxi Health Commission
  • Scientific Research Program of Wuxi Health Commission

Zitieren

APA

Qiang, X., Zhou, G., Xu, R., Chen, F., Lu, J., Sun, W., Tian, Y., Yang, X., Tang, Q., & Ye, M. (2026). Lansoprazole Enhances Everolimus Efficacy Through DDIT3 ‐Mediated PI3K / AKT /mTOR Pathway Inhibition in Pancreatic Neuroendocrine Neoplasms Proliferation. The FASEB Journal, 40(7). https://doi.org/10.1096/fj.202600037r

Vancouver

Qiang X, Zhou G, Xu R, Chen F, Lu J, Sun W, et al. Lansoprazole Enhances Everolimus Efficacy Through DDIT3 ‐Mediated PI3K / AKT /mTOR Pathway Inhibition in Pancreatic Neuroendocrine Neoplasms Proliferation. The FASEB Journal. 2026;40(7). doi:10.1096/fj.202600037r

BibTeX
@article{Qiang2026,
  author = {Qiang, Xinyun and Zhou, Guozhi and Xu, Ruitong and Chen, Fengjuan and Lu, Jieyu and Sun, Wei and Tian, Ye and Yang, Xiaojun and Tang, Qiyun and Ye, Mujie},
  title = {Lansoprazole Enhances Everolimus Efficacy Through DDIT3 ‐Mediated PI3K / AKT /mTOR Pathway Inhibition in Pancreatic Neuroendocrine Neoplasms Proliferation},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.1096/fj.202600037r}
}
Kostenlos starten →